Lupin Limited has informed the Exchange regarding a press release dated May 29, 2026, titled "Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets".
Press Release May 29 2026
Filed with NSE · · 2 pages · English
Release
Earlier from Lupin
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Press Release May 28 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Press Release May 22 2026
- Press Release May 19 2026
Later from Lupin
- Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
- Press Release Jun 03 2026
- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Press Release Jun 04 2026
- Lupin Receives Approval from U.S. FDA for Ranluspec™(ranibizumab) Injection
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin